<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Regeneron Pharmaceuticals</strong> (NASDAQ:REGN).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 13 options trades for <strong>Regeneron Pharmaceuticals</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 38% bullish and 30%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $56,100, and 12, calls, for a total amount of $540,338.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $400.0 and $1000.0 for Regeneron Pharmaceuticals, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale trades within a strike price range from $400.0 to $1000.0 in the last 30 days. </p>
<h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766512900_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Options Call Chart" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766512900_0.png"/></p>

<h3>Significant Options Trades Detected:</h3>
<p></p><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/20/26</td>
<td>$134.6</td>
<td>$128.1</td>
<td>$131.5</td>
<td>$670.00</td>
<td>$78.9K</td>
<td align="right">11</td>
<td align="right">12</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$38.6</td>
<td>$37.2</td>
<td>$37.4</td>
<td>$760.00</td>
<td>$56.1K</td>
<td align="right">13</td>
<td align="right">17</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/15/26</td>
<td>$60.0</td>
<td>$58.0</td>
<td>$58.0</td>
<td>$820.00</td>
<td>$52.2K</td>
<td align="right">137</td>
<td align="right">27</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$1000.00</td>
<td>$49.0K</td>
<td align="right">108</td>
<td align="right">10</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$69.9</td>
<td>$66.5</td>
<td>$69.9</td>
<td>$760.00</td>
<td>$48.9K</td>
<td align="right">102</td>
<td align="right">7</td>
</tr>
</tbody>
</table><p></p>
<h3>About Regeneron Pharmaceuticals</h3>
<p>Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).</p>
<p>After a thorough review of the options trading surrounding Regeneron Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Regeneron Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 246,591, the REGN's price is down by -0.17%, now at $778.0. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 42 days.</li>
</ul>
<h3>Professional Analyst Ratings for Regeneron Pharmaceuticals</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $786.2.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $798.
* Consistent in their evaluation, an analyst from Scotiabank keeps a Sector Perform rating on Regeneron Pharmaceuticals with a target price of $770. 
* An analyst from Wells Fargo persists with their Equal-Weight rating on Regeneron Pharmaceuticals, maintaining a target price of $745. 
* Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Regeneron Pharmaceuticals, targeting a price of $850. 
* Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Regeneron Pharmaceuticals, targeting a price of $768. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from Benzinga Pro.</p>

REGN

<p>Investors are showing interest in Regeneron Pharmaceuticals with significant options activity detected. The sentiment is mixed, with 38% bullish and 30% bearish. Major market movers focus on a price band between $400 and $1000. Analysts have varied ratings, with price targets ranging from $745 to $850. The stock is currently trading at $778, down 0.17%. Options trading presents higher risks and rewards, requiring careful monitoring and strategy adaptation.</p>

Regeneron Pharmaceuticals's Options Frenzy: What You Need to Know